U.S. stock market midday update: Liminatus Pharma up 15.09%, trading volume surges, market sentiment is high but beware of volatility risks

U.S. Stock Market Midday Update Liminatus Pharma, up 15.09%, with increased trading volume and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks Ranking High in Industry Transaction Volume AbbVie, up 0.18%. Based on recent key news: On April 15, Rongchang Biologics announced it had signed an exclusive licensing agreement with AbbVie, receiving a $650 million upfront payment. This move has enhanced market confidence in AbbVie, driving the stock price up. On April 14, AbbVie announced plans to expand manufacturing capabilities in the U.S., investing $380 million to support long-term growth and commercialization. This strategy has raised market expectations for AbbVie's future development, promoting the stock price increase. On April 13, Haisco and AbbVie reached a cooperation agreement to develop a new pain relief drug. This collaboration has established an international benchmark for AbbVie in pain management, further driving the stock price up. Competition in the innovative drug industry is intensifying, with significant capital inflow. Revolution Medicines, down 0.82%. Based on recent key news: On April 14, Revolution Medicines announced that its pancreatic cancer drug daraxonrasib significantly extended patient survival in late-stage trials, causing the stock price to rise by 41.3%. The drug nearly doubled the survival time to 13.2 months compared to 6.7 months for the chemotherapy group, pushing the stock price to a new high. Source: Reuters On April 15, the company announced the pricing of a $2 billion stock and convertible senior notes offering, with the stock price rising 1.35% in pre-market trading. The scale of this offering is larger than previously planned and is expected to be used for R&D and potential commercialization. Source: Zhitong Finance On April 14, analysts are generally optimistic about Revolution Medicines, with 9 out of 21 analysts giving a "strong buy" rating, and a median target price of $145. Analysts believe the drug could become the new standard for pancreatic cancer treatment. Source: Reuters The U.S. stock market is experiencing increased volatility, with capital flowing into the technology sector. Amgen, down 0.28%, with increased trading volume. Based on recent key news: On April 15, BeiGene released its financial report, showing a revenue growth of 40.46% and a return to profitability. Amgen, as a core shareholder with a 17.09% stake, may see this news affect investor confidence, leading to stock price volatility. On April 16, the sales of Innovent Biologics' tocilizumab saw significant growth, becoming a core growth driver for local companies. Increased competition in the industry may affect Amgen's market performance, leading to stock price volatility. On April 16, Amgen's annualized return over the past 15 years has been 13.27%, outperforming the market. Long-term investors may take a wait-and-see approach to recent stock price fluctuations. Competition in the pharmaceutical industry is intensifying, with significant policy impacts Stocks Ranked Among the Top by Market Capitalization in the Industry Gilead Sciences fell by 0.82%. Based on recent news, On April 14, the U.S. State Department announced an expansion of cooperation with Gilead Sciences and the Global Fund to increase access to the breakthrough HIV prevention drug Lenacapavir. This initiative aims to cover 3 million people by 2028, driving stock price volatility. On April 14, Connoa-B received a $250 million upfront payment from Gilead's acquisition of Ouro Medicines, prompting Guosen Securities to raise its earnings forecast, indirectly affecting Gilead's stock price. On April 14, protests in San Francisco condemned Gilead's high pricing of AIDS medications, raising market concerns and leading to a decline in stock prices. Significant impacts from macroeconomic dynamics and active capital flows